Dendritic cells enhance tebentafusp-mediated T cell effector responses

Tebentafusp is the first approved T cell receptor (TCR)-based bispecific therapy and prolongs survival in metastatic uveal melanoma by redirecting T cells against gp100/HLA-A*02:01-positive tumor cells. However, how tebentafusp reshapes immune-cell interactions within the tumor microenvironment remains incompletely understood. Here, using HLA-defined donor T cells, dendritic cells (DCs), and tumor cell models with distinct gp100 and HLA-A*02:01 expression profiles, we identify a DC-dependent mechanism that enhances tebentafusp-mediated T cell activation, cytokine production, and cytotoxicity. Across the tumor cell models, the magnitude of tebentafusp-mediated functional responses was closely associated with gp100 abundance and HLA-A*02:01 surface expression. This DC-dependent enhancement was not explained by conventional antigen presentation or the tested CD80/CD86 pathway and was not further enhanced by PD-1 or CTLA-4 blockade. Notably, following direct co-culture with gp100-positive, HLA-A*02:01-positive tumor cells, HLA-A*02:01-negative DCs displayed surface-bound tebentafusp and subsequently enabled tebentafusp-specific T cell activation despite the HLA mismatch. Transfer required gp100 and HLA-A*02:01 expression as well as direct cell–cell contact, consistent with functional DC cross-dressing. Together, these findings reveal a DC-mediated amplification mechanism that extends tebentafusp activity beyond direct tumor–T cell interactions and may shape immune redirection within the tumor microenvironment.

Authors

Institutions

Publication Details

Journal
Cancer Immunology Immunotherapy
Published
2026-11-14
DOI
https://doi.org/10.1007/s00262-026-04609-3
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Dendritic cells enhance tebentafusp-mediated T cell effector responses

Kilian Schober, Markus Luber, Elias A. T. Koch, Anne Petzold et al.
Cancer Immunology Immunotherapy
Immunotherapy and Immune Responses
article

Dendritic cells enhance tebentafusp-mediated T cell effector responses

Kilian Schober, Markus Luber, Elias A. T. Koch, Anne Petzold, Manuel Wiesinger, Beatrice Schuler‐Thurner, Markus Vincent Heppt, Philipp Hilgendorf, Carola Berking, Andreas Wild
article en

Abstract

Tebentafusp is the first approved T cell receptor (TCR)-based bispecific therapy and prolongs survival in metastatic uveal melanoma by redirecting T cells against gp100/HLA-A*02:01-positive tumor cells. However, how tebentafusp reshapes immune-cell interactions within the tumor microenvironment remains incompletely understood. Here, using HLA-defined donor T cells, dendritic cells (DCs), and tumor cell models with distinct gp100 and HLA-A*02:01 expression profiles, we identify a DC-dependent mechanism that enhances tebentafusp-mediated T cell activation, cytokine production, and cytotoxicity. Across the tumor cell models, the magnitude of tebentafusp-mediated functional responses was closely associated with gp100 abundance and HLA-A*02:01 surface expression. This DC-dependent enhancement was not explained by conventional antigen presentation or the tested CD80/CD86 pathway and was not further enhanced by PD-1 or CTLA-4 blockade. Notably, following direct co-culture with gp100-positive, HLA-A*02:01-positive tumor cells, HLA-A*02:01-negative DCs displayed surface-bound tebentafusp and subsequently enabled tebentafusp-specific T cell activation despite the HLA mismatch. Transfer required gp100 and HLA-A*02:01 expression as well as direct cell–cell contact, consistent with functional DC cross-dressing. Together, these findings reveal a DC-mediated amplification mechanism that extends tebentafusp activity beyond direct tumor–T cell interactions and may shape immune redirection within the tumor microenvironment.

Cancer Immunology Immunotherapy
Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), Universitätsklinikum Erlangen (DE), Comprehensive Cancer Center Erlangen (DE)
Universitätsklinikum Erlangen
Good health and well-being
Immunotherapy and Immune Responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon